Short term effects of L-carnitine on serum lipids in STZ-induced diabetic rats

Diabetes Research and Clinical Practice

Volumn 66, Issue 2, 2004, Pages 129-132

  Eskandari, H Gulcin ^a   Cimen, M Y Burak ^a   Tamer, Lulufer ^a   Kanik, Arzu ^a   Atik, Ugur ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Diabetes; L Carnitine; Streptozotocin; Total cholesterol; Triglycerides

Indexed keywords

BUFFER; CARNITINE; CHOLESTEROL; CITRIC ACID; LIPID; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; EVALUATION; HYPOCHOLESTEROLEMIA; MALE; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CARNITINE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; MALE; RATS; RATS, WISTAR; TIME FACTORS; TRIGLYCERIDES;

EID: 7944224302     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.03.005     Document Type: Conference Paper

References (24)

1. M.A. Sperling, Diabetes mellitus, in: R.E. Behrman, R.M. Kliegman, H.B. Jenson (Eds.), Nelson Textbook of Pediatrics, Saunders, PA, 2000, pp. 1767-1791.
2. N.V. Bhagavan, Metabolic homeostasis, in: N.V. Baghavan (Ed.), Medical Biochemistry, Harcourt/Academic, Florida, 2002, pp. 485-519.
3. N.V. Bhagavan, Lipids III: plasma lipoproteins, in: N.V. Baghavan (Ed.), Medical Biochemistry, Harcourt/Academic, Florida, 2002, pp. 429-451.
4. Ohno T., Horio F., Tanaka S., Terada M., Namikawa T., Kitoh J. Fatty liver and hyperlipidemia in IDDM (insulin-dependent diabetes mellitus) of Streptozotocin-treated shrews. Life Sci. 66:2000;125-131
5. Dyck J.R., Berthiaume L.G., Thomas P.D., et al. Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism. Biochem. J. 350:2000;599-608
6. Ranganathan G., Li C., Kern P.A. The translational regulation of lipoprotein lipase in diabetic rats involves the 3′-untranslated region of the lipoprotein lipase mRNA. J. Biol. Chem. 275:2000;40986-40991
7. Diaz M., Lopez F., Hernandez F., Urbina J.A. L-carnitine effects on chemical composition of plasma lipoproteins of rabbits fed with normal and high cholesterol diets. Lipids. 35:2000;627-632
8. Peluso G., Nicolai R., Reda E., Benatti P., Barbarisi A., Calvani M. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J. Cell. Physiol. 182:2000;339-350
9. Saheki T. Carnitine as a vitamin-like biofactor. Nippon Rinsho. 57:1999;2270-2275
10. Williamson J.R., Arrigoni-Martelli E. The roles of glucose-induced metabolic imbalances in carnitine metabolism in mediating diabetes-induced vascular dysfunction. Int. J. Clin. Pharmacol. Res. 12:1992;247-252
11. Coker M., Coker C., Darcan S., Can S., Orbak Z., Goksen D. Carnitine metabolism in diabetes mellitus. J. Pediatr. Endocrinol. Metab. 15:2002;841-849
12. Ginsberg H.N. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care. 14:1991;839-855
13. Coppack S.W., Jensen M.D., Miles J.M. In vivo regulation of lipolysis in humans. J. Lipid Res. 35:1994;177-193
14. Rubba P., Capaldo B., Falanga A., et al. Plasma lipoproteins and lipoprotein lipase in young diabetics with and without ketonuria. Endocrinol. Invest. 8:1985;433-436
15. Taskinen M.R. LDL-cholesterol, HDL-cholesterol or triglycerides- which is the culprit? Diabetes Res. Clin. Pract. 61:2003;S19-S26
16. Winocour P.H., Durrington P.N., Bhatnagar D., Ishola M., Arrol S., Mackness M. Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. Arterioscler. Thromb. 12:1992;920-928
17. Tso T.K., Snook J.T., Lozano R.A., Zipf W.B. Risk factors for coronary heart disease in type 1 diabetic children: the influence of apo E phenotype and glycemic regulation. Diabetes Res. Clin. Pract. 54:2001;165-171
18. Akanji A.O., Abdella N., Mojiminiyi O.A. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidemic patients in Kuwait. Clin. Chim. Acta. 317:2002;171-176
19. Verges B.L. Dyslipidemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab. 25:1999;32-40
20. Dai S., McNeill J.H. Ascorbic acid supplementation prevents hyperlipidemia and improves myocardial performance in streptozotocin-diabetic rats. Diabetes Res. Clin. Pract. 27:1995;11-18
21. Tsutsumi K., Inoue Y., Shima A., Murase T. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes. 44:1995;414-417
22. Yin W., Liao D., Wang Z., Xi S., et al. NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-α and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs. Pharmacol. Res. 49:2004;199-206
23. Shah T.S., Satia M.C., Gandhi T.P., Bangaru R.A., Goyal R.K. Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats. J. Cardiovasc. Pharmacol. 26:1995;6-12
24. Dellow W.J., Chambers S.T., Lever M., Lunt H., Robson R.A. Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. Diabetes Res. Clin. Pract. 43:1999;91-99